NES-ZIONA, ISRAEL / ACCESSWIRE / April 14, 2023 / This month, H.C. Wainwright & Co. reiterated its buy rating for Enlivex Therapeutics Ltd. (NASDAQ:ENLV) with a 12-month price target of $15 per share, based on a valuation estimated at $320 million. Despite forecasting a net loss of $1.75 per share in 2023 largely due to high R&D spend, analysts believe the clinical-stage company's $50.2 million in cash and short-term deposits is enough to fund operations through to the second half of 2024. Meanwhile, Enlivex is expecting topline data from multiple ongoing clinical trials for its novel macrophage reprogramming immunotherapy, Allocetra, including a recent high-profile collaboration with BeiGene Ltd throughout the end of 2023 and early 2024. Here's a look at some of the promising developments behind the buy rating.

Research Report: https://storage.googleapis.com/accesswire/media/749241/ENLV-Apr-5-2023-1.pdf

Photo by National Cancer Institute on Unsplash

The Recent BeiGene Collaboration Could Set The Stage For Broader Applications Across Checkpoint Inhibitor Market

Earlier this month, Enlivex announced a new collaboration agreement with BeiGene, one of the world's leading developers of cancer therapies. Under the agreement, Enlivex will amend its current, ongoing phase 1/2a clinical trial of Allocetra as a treatment for advanced-stage solid tumors to include a second stage of patients that will be treated with a combination of Allocetra and BeiGene's Tislelizumab.

Tislelizumab is an anti-PD-1 checkpoint inhibitor, a class of immunotherapies that have shown a lot of promise in treating many types of cancers. But they have had limited success in treating solid cancers because they struggle to break through a tumor's immune microenvironment.

To overcome that barrier, BeiGene and other developers have been looking for combination regimens that could improve the results of their checkpoint inhibitors across these difficult-to-treat cancers. So far, that effort has been met with a series of failures. Last April, for example, Bristol Myers Squibb announced two failed clinical trials that were evaluating a combination of Opdivo and BEMPEG, Nektar Therapeutics' immunotherapy drug candidate. In March, Merck also reported two failed clinical trials, one combining Keytruda with chemotherapy and another combining it with a hormone therapy.

So positive results in the Allocetra-Tislelizumab trial would be a major step forward in the checkpoint inhibitor space and put Enlivex's drug candidate in a position to be used in combination with other checkpoint inhibitors in the market.